FDG-PET Detail by Tumor
- FDG is radioactive sugar. PET lights up cells that are hungry for sugar — which most aggressive tumors are — but plenty of innocent cells are hungry too.
- "Avid" just means bright. The dial for brightness is the SUV, a rough number for how much tracer piled up relative to the rest of the body.
- The key skill isn't reading the scan — it's knowing which tumors deserve FDG. Some cancers glow beautifully; others are nearly invisible and will fool you.
- Brown fat, infection, muscle, and a recent meal can all out-shine a tumor. Context is everything.
FDG-PET is the radiology version of following the smell of fresh donuts. You inject a sugar that cells gobble up, tag it so it glows, and then watch which parts of the body are the hungriest. Cancer, being metabolically greedy, usually eats more than its neighbors and lights up like a streetlamp. Simple idea, enormous footprint in oncology — but the catch is that not every cancer is hungry, and not everything hungry is cancer. This page is about which tumors actually play by these rules.
What FDG actually is
FDG stands for fluorodeoxyglucose — glucose with a radioactive fluorine bolted on where one oxygen should be. Cells grab it just like normal sugar, start to metabolize it, and then get stuck partway through. The tracer can't finish the reaction, so it's trapped inside the cell, piling up exactly where the appetite is biggest. The trapped tracer decays and the PET scanner maps the glow. (If the trapping-and-glowing physics is fuzzy, the PET physics page is the place to firm it up.)
The brightness gets a number called the SUV (standardized uptake value) — basically "how concentrated is the tracer here versus if it were spread evenly through the whole body." A spot brighter than expected is called FDG-avid. Don't over-trust the exact decimal; SUV drifts with patient size, blood sugar, and how long you waited after injecting. Treat it as a fuzzy dial, not a lab value.
"Avid" = bright = hungry for sugar. It is not a synonym for "cancer." It's a synonym for "metabolically busy," and busy comes in many innocent flavors.
The hungry, the shy, and the snackers
Here's the part worth memorizing: FDG is fantastic for some tumors and nearly useless for others. The pattern follows metabolism. Fast, aggressive, sugar-burning tumors blaze. Slow, well-differentiated, or mucinous tumors barely whisper.
| Tumor behavior on FDG | Typical examples | Why |
|---|---|---|
| Reliably bright | Most lymphomas, many lung cancers, melanoma, head & neck squamous cell, esophageal | High metabolic turnover; classic FDG customers |
| Often dim or unreliable | Well-differentiated neuroendocrine tumors, prostate adenocarcinoma, many renal cell cancers, mucinous tumors, low-grade tumors | Slow metabolism, or biology that just doesn't crave glucose |
| Naturally bright background nearby | Brain, liver, anything along the urinary tract | Normal tissue out-glows the target |
That middle row is where careers in over-reading and under-reading are made. A faint or negative FDG scan in a prostate cancer doesn't reassure you of anything — that tumor was never going to glow, which is exactly why we built PSMA-PET for it. Same story for well-differentiated neuroendocrine tumors, which prefer a DOTATATE tracer. Picking the wrong tracer is like searching for your friend in a dark room by smell when they aren't wearing the perfume.
A "negative" FDG-PET only means something if the tumor was the kind that should light up. For shy tumors, a cold scan proves nothing — you needed a different tracer from the start.
Where FDG earns its keep
When the tumor is the bright kind, FDG-PET shines at the jobs anatomy alone struggles with: finding distant metastases the CT missed, telling a dead post-treatment scar (cold) from living residual tumor (hot), and hunting an unknown primary when only a metastasis showed up first. In lymphoma especially, it's central to both staging and judging response after therapy.
The impostors
FDG's great weakness is that anything burning sugar lights up, and the body is full of metabolically busy innocents. This is where the traps live.
Classic non-tumor FDG hotspots that fool people: brown fat in the neck and shoulders (symmetric, follows fat, worse when cold), active infection or inflammation (an abscess can out-glow a tumor), skeletal muscle in a tense or recently exercising patient, bowel and vocal cords, and post-treatment changes for weeks after surgery, radiation, or biopsy. When a finding doesn't fit the cancer story, suspect one of these first.
Two practical guardrails. First, prep matters: patients fast beforehand because a sugary meal floods the body with competing glucose and dims the tumor, and high blood sugar can wreck the whole study. Second, timing matters: scanning too soon after treatment catches the inflammatory bonfire, not the cancer, so we usually wait. Sorting out inflammation from tumor is a whole skill of its own — see infection and inflammation imaging.
Before you call a hot spot cancer, ask three questions: Is this the kind of tumor that glows? Could this be brown fat, infection, muscle, or treatment effect? Does the anatomy on the fused CT actually support it? If all three pass, then believe the glow.
The one thing to carry out
FDG-PET doesn't find cancer — it finds appetite, and then you decide whether that appetite is malignant. Match the tracer to the tumor, respect the impostors, and read the glow alongside the CT rather than instead of it. Do that, and the donut detector becomes one of the most powerful tools in oncologic imaging.